Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet·
- DOI
- 10.1016/s0140-6736(26)00258-8
- PMID
- 42035777
- PMCID
- PMC13266303
- OpenAlex
- W7155420337
- Study type
- Randomised controlled trial
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
These outcomes indicate that targeted immunoprophylaxis may serve as a supplementary preventive measure for youth in endemic zones, though current dosing regimens require optimization for maximum impact.
Structured evidence summary
Research question
What is the safety profile and protective effectiveness of the monoclonal antibody L9LS against Plasmodium falciparum infection in pediatric patients residing in an area with continuous disease circulation?
Study design
Researchers conducted a double-blind, randomized, placebo-controlled phase 2 evaluation utilizing sequential dosing cohorts and extended clinical monitoring. Participants received either the investigational biologic or saline solution under centralized allocation procedures.
Population and setting
Healthy children between five months and ten years old participated in the assessment within Siaya county, Kenya, a region experiencing year-round pathogen exposure.
Main findings
Children receiving two administrations of the antibody experienced a lower rate of confirmed infections compared to those given saline, yielding roughly forty-three percent protection over one year. Mild treatment-related reactions occurred occasionally and resolved completely, while no severe complications linked to the study protocol were documented.
Public-health relevance
These outcomes indicate that targeted immunoprophylaxis may serve as a supplementary preventive measure for youth in endemic zones, though current dosing regimens require optimization for maximum impact.
Important limitations
The investigation was restricted to a single Kenyan district and monitored participants for only twelve months following initial administration. Furthermore, the measured protective effect did not reach the magnitude typically desired for intensive transmission environments.
GIDS interpretation
This peer-reviewed report documents early-stage clinical testing of a biological countermeasure for a tropical infectious disease. The dataset offers structured reference points for tracking therapeutic development trajectories and understanding regional pediatric health interventions.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.